Accelerate Cost Of Revenue vs Capex To Revenue Analysis

AXDX Stock

USD 1.66 0.05 3.11%

Accelerate Diagnostics financial indicator trend analysis is way more than just evaluating Accelerate Diagnostics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Accelerate Diagnostics is a good investment. Please check the relationship between Accelerate Diagnostics Cost Of Revenue and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Accelerate Diagnostics Cost Of Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have very week relationship.

The correlation between Accelerate Diagnostics' Cost Of Revenue and Capex To Revenue is 0.24. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Accelerate Diagnostics, assuming nothing else is changed. The correlation between historical values of Accelerate Diagnostics' Cost Of Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Accelerate Diagnostics are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Cost Of Revenue i.e., Accelerate Diagnostics' Cost Of Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.24

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Accelerate Diagnostics income statement and represents the costs associated with goods and services Accelerate Diagnostics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Accelerate Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Accelerate Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.At this time, Accelerate Diagnostics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 219.4 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3.8 M in 2024.

	2023	2024 (projected)
Interest Income	1.3M	1.2M
Non Recurring	2.7K	2.4K

Interest Income Non Recurring

Accelerate Diagnostics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock Total Equity	Common Stock	Current Deferred Revenue	Other Liab	Other Assets	Treasury Stock
Total Assets		0.78	0.04	0.43	0.7	0.08	-0.21	0.14	0.76	0.54	0.02	0.98	0.25	0.14	0.52	-0.14	0.32	0.51	0.25	1.0	-0.58	-0.57	-0.1	-0.68	0.04	-0.32
Other Current Liab	0.78		0.26	-0.06	0.81	0.52	-0.67	0.44	0.38	0.76	-0.26	0.66	0.71	0.54	0.7	0.37	0.72	0.73	0.69	0.75	-0.55	-0.52	0.34	-0.5	0.16	-0.73
Total Current Liabilities	0.04	0.26		-0.27	0.37	0.25	-0.54	0.6	0.04	0.37	-0.04	-0.03	0.43	0.28	0.02	0.29	0.53	0.29	0.3	0.02	-0.26	-0.25	0.23	0.35	0.11	-0.47
Total Stockholder Equity	0.43	-0.06	-0.27		-0.24	-0.82	0.55	-0.18	0.47	-0.41	0.59	0.55	-0.51	-0.25	-0.5	-0.59	-0.37	-0.55	-0.4	0.47	-0.12	-0.12	-0.25	-0.23	-0.59	0.66
Property Plant And Equipment Net	0.7	0.81	0.37	-0.24		0.59	-0.66	0.38	0.46	0.94	-0.29	0.6	0.65	0.35	0.81	0.28	0.65	0.88	0.58	0.66	-0.61	-0.6	0.1	-0.48	0.45	-0.77
Net Debt	0.08	0.52	0.25	-0.82	0.59		-0.66	0.14	-0.3	0.7	-0.7	-0.06	0.69	0.28	0.81	0.5	0.52	0.84	0.5	0.03	-0.13	-0.14	0.23	-0.26	0.64	-0.83
Retained Earnings	-0.21	-0.67	-0.54	0.55	-0.66	-0.66		-0.8	-0.02	-0.73	0.25	-0.03	-0.86	-0.83	-0.55	-0.86	-0.98	-0.66	-0.91	-0.16	0.53	0.52	-0.69	-0.1	-0.31	0.9
Accounts Payable	0.14	0.44	0.6	-0.18	0.38	0.14	-0.8		0.19	0.39	0.18	0.0	0.65	0.88	0.07	0.78	0.86	0.21	0.83	0.11	-0.55	-0.55	0.75	0.36	-0.12	-0.56
Cash	0.76	0.38	0.04	0.47	0.46	-0.3	-0.02	0.19		0.29	0.26	0.79	-0.03	0.05	0.25	-0.19	0.13	0.25	0.12	0.77	-0.46	-0.44	-0.25	-0.3	-0.05	-0.11
Non Current Assets Total	0.54	0.76	0.37	-0.41	0.94	0.7	-0.73	0.39	0.29		-0.44	0.41	0.75	0.38	0.82	0.4	0.69	0.89	0.63	0.49	-0.39	-0.43	0.18	-0.35	0.48	-0.82
Non Currrent Assets Other	0.02	-0.26	-0.04	0.59	-0.29	-0.7	0.25	0.18	0.26	-0.44		0.1	-0.34	0.09	-0.58	-0.22	-0.11	-0.57	-0.14	0.05	-0.26	-0.28	-0.08	0.33	-0.77	0.43
Cash And Short Term Investments	0.98	0.66	-0.03	0.55	0.6	-0.06	-0.03	0.0	0.79	0.41	0.1		0.08	0.0	0.42	-0.31	0.16	0.4	0.08	0.99	-0.52	-0.5	-0.25	-0.69	-0.02	-0.17
Net Receivables	0.25	0.71	0.43	-0.51	0.65	0.69	-0.86	0.65	-0.03	0.75	-0.34	0.08		0.65	0.58	0.69	0.83	0.66	0.81	0.21	-0.31	-0.31	0.66	-0.15	0.16	-0.85
Common Stock Shares Outstanding	0.14	0.54	0.28	-0.25	0.35	0.28	-0.83	0.88	0.05	0.38	0.09	0.0	0.65		0.22	0.9	0.89	0.27	0.93	0.12	-0.58	-0.58	0.83	0.23	-0.07	-0.61
Non Current Liabilities Total	0.52	0.7	0.02	-0.5	0.81	0.81	-0.55	0.07	0.25	0.82	-0.58	0.42	0.58	0.22		0.3	0.46	0.96	0.48	0.48	-0.33	-0.33	0.01	-0.56	0.62	-0.8
Other Current Assets	-0.14	0.37	0.29	-0.59	0.28	0.5	-0.86	0.78	-0.19	0.4	-0.22	-0.31	0.69	0.9	0.3		0.83	0.34	0.89	-0.17	-0.35	-0.35	0.84	0.33	0.21	-0.68
Other Stockholder Equity	0.32	0.72	0.53	-0.37	0.65	0.52	-0.98	0.86	0.13	0.69	-0.11	0.16	0.83	0.89	0.46	0.83		0.57	0.92	0.29	-0.62	-0.62	0.73	0.07	0.18	-0.83
Total Liab	0.51	0.73	0.29	-0.55	0.88	0.84	-0.66	0.21	0.25	0.89	-0.57	0.4	0.66	0.27	0.96	0.34	0.57		0.53	0.47	-0.38	-0.38	0.05	-0.45	0.63	-0.89
Property Plant And Equipment Gross	0.25	0.69	0.3	-0.4	0.58	0.5	-0.91	0.83	0.12	0.63	-0.14	0.08	0.81	0.93	0.48	0.89	0.92	0.53		0.22	-0.55	-0.55	0.76	0.05	0.12	-0.79
Total Current Assets	1.0	0.75	0.02	0.47	0.66	0.03	-0.16	0.11	0.77	0.49	0.05	0.99	0.21	0.12	0.48	-0.17	0.29	0.47	0.22		-0.57	-0.56	-0.12	-0.68	0.01	-0.28
Common Stock Total Equity	-0.58	-0.55	-0.26	-0.12	-0.61	-0.13	0.53	-0.55	-0.46	-0.39	-0.26	-0.52	-0.31	-0.58	-0.33	-0.35	-0.62	-0.38	-0.55	-0.57		0.97	-0.32	0.26	-0.16	0.43
Common Stock	-0.57	-0.52	-0.25	-0.12	-0.6	-0.14	0.52	-0.55	-0.44	-0.43	-0.28	-0.5	-0.31	-0.58	-0.33	-0.35	-0.62	-0.38	-0.55	-0.56	0.97		-0.3	0.22	-0.14	0.42
Current Deferred Revenue	-0.1	0.34	0.23	-0.25	0.1	0.23	-0.69	0.75	-0.25	0.18	-0.08	-0.25	0.66	0.83	0.01	0.84	0.73	0.05	0.76	-0.12	-0.32	-0.3		0.2	-0.06	-0.41
Other Liab	-0.68	-0.5	0.35	-0.23	-0.48	-0.26	-0.1	0.36	-0.3	-0.35	0.33	-0.69	-0.15	0.23	-0.56	0.33	0.07	-0.45	0.05	-0.68	0.26	0.22	0.2		-0.27	0.12
Other Assets	0.04	0.16	0.11	-0.59	0.45	0.64	-0.31	-0.12	-0.05	0.48	-0.77	-0.02	0.16	-0.07	0.62	0.21	0.18	0.63	0.12	0.01	-0.16	-0.14	-0.06	-0.27		-0.44
Treasury Stock	-0.32	-0.73	-0.47	0.66	-0.77	-0.83	0.9	-0.56	-0.11	-0.82	0.43	-0.17	-0.85	-0.61	-0.8	-0.68	-0.83	-0.89	-0.79	-0.28	0.43	0.42	-0.41	0.12	-0.44

Click cells to compare fundamentals

Accelerate Diagnostics Account Relationship Matchups

Accelerate Diagnostics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	134.4M	93.4M	83.0M	65.0M	31.4M	48.2M
Other Current Liab	5.1M	3.8M	3.1M	3.2M	3.4M	3.6M
Total Current Liabilities	8.2M	7.0M	6.9M	66.6M	12.0M	12.6M
Total Stockholder Equity	(7.4M)	(62.8M)	(35.1M)	(22.3M)	(19.9M)	(18.9M)
Property Plant And Equipment Net	11.8M	9.3M	7.9M	7.8M	5.1M	2.7M
Net Debt	73.1M	114.2M	71.2M	42.6M	27.1M	28.4M
Retained Earnings	(414.7M)	(493.0M)	(570.7M)	(607.2M)	(668.9M)	(635.4M)
Accounts Payable	2.4M	1.3M	2.0M	4.5M	4.8M	5.0M
Cash	61.0M	35.8M	39.9M	34.9M	12.1M	23.7M
Non Current Assets Total	12.6M	11.4M	9.7M	9.0M	6.9M	5.4M
Non Currrent Assets Other	750K	(5.9M)	1.8M	1.2M	1.8M	1.9M
Cash And Short Term Investments	108.5M	68.3M	63.6M	45.6M	13.2M	12.6M
Net Receivables	3.2M	1.6M	2.3M	2.4M	2.6M	2.8M
Common Stock Shares Outstanding	5.4M	5.5M	5.6M	6.2M	12.5M	13.1M
Liabilities And Stockholders Equity	134.4M	93.4M	83.0M	65.0M	31.4M	48.2M
Non Current Liabilities Total	133.6M	149.3M	111.2M	20.7M	39.2M	23.3M
Other Current Assets	1.2M	3.0M	2.3M	2.0M	5.3M	5.6M
Other Stockholder Equity	407.3M	430.0M	535.6M	585.3M	649.6M	682.0M
Total Liab	141.8M	156.2M	118.1M	87.3M	51.3M	28.6M
Property Plant And Equipment Gross	11.8M	9.3M	7.9M	7.8M	16.1M	16.9M
Total Current Assets	121.9M	82.0M	73.3M	56.0M	24.5M	42.8M
Accumulated Other Comprehensive Income	(58K)	91K	(60K)	(400K)	(612K)	(581.4K)
Common Stock Total Equity	56K	54K	55K	58K	52.2K	49.6K
Common Stock	55K	58K	68K	97K	14K	13.3K
Current Deferred Revenue	271K	376K	451K	547K	1.5M	1.6M
Other Liab	19K	335K	808K	1.5M	1.4M	1.5M
Other Assets	750K	5.3M	1.8M	1.2M	1.0	0.95
Property Plant Equipment	7.9M	6.1M	7.9M	7.8M	8.9M	9.4M
Inventory	8.1M	9.2M	5.1M	5.2M	3.3M	2.7M
Net Tangible Assets	(7.4M)	(62.8M)	(35.1M)	(22.3M)	(20.0M)	(19.0M)
Long Term Debt	130.0M	145.9M	108.0M	16.9M	36.1M	51.1M
Retained Earnings Total Equity	(330.3M)	(414.7M)	(493.0M)	(570.7M)	(513.6M)	(487.9M)
Short Term Investments	47.4M	32.5M	23.7M	10.7M	1.1M	1.0M
Capital Surpluse	432.9M	452.3M	475.1M	580.7M	667.7M	701.1M
Non Current Liabilities Other	3.6M	3.4M	3.2M	874K	1.2M	1.6M
Short Long Term Debt Total	134.1M	150.0M	111.1M	77.5M	39.2M	37.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Accelerate Cost Of Revenue vs Capex To Revenue Analysis

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Capex To Revenue

Accelerate Diagnostics fundamental ratios Correlations

Accelerate Diagnostics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Accelerate Diagnostics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Accelerate Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock	+ 0.97	Common Stock Total Equity
Total Liab	+ 0.96	Non Current Liabilities Total
Non Current Assets Total	+ 0.94	Property Plant And Equipment Net

Other Stockholder Equity	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.91	Retained Earnings
Treasury Stock	- 0.89	Total Liab
Other Current Assets	- 0.86	Retained Earnings
Net Receivables	- 0.86	Retained Earnings
Treasury Stock	- 0.85	Net Receivables